A carregar...

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?

Compelling evidence indicates Type I CD20 immunotherapeutic mAbs promote targeted tumor cell elimination exclusively via immune effector functions, which can be exhausted/saturated. mAb dosing paradigms should therefore take into account the capacity of these cytotoxic mechanisms, leading to the con...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lindorfer, Margaret A., Wiestner, Adrian, Zent, Clive S., Taylor, Ronald P.
Formato: Artigo
Idioma:Inglês
Publicado em: Landes Bioscience 2012
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3489759/
https://ncbi.nlm.nih.gov/pubmed/23162771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.20368
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!